Your browser doesn't support javascript.
loading
High prevalence of olfactory dysfunction detected in treatment-naive patients with head and neck cancer.
Barbosa da Silva, José Lucas; Anzolin, Lucas Kanieski; Nicacio, Samuel Pissinati; Doty, Richard L; Pinna, Fábio de Rezende; Voegels, Richard Louis; Fornazieri, Marco Aurélio.
Afiliação
  • Barbosa da Silva JL; Department of Clinical Surgery, State University of Londrina, Londrina, Brazil.
  • Anzolin LK; Department of Otorhinolaryngology, University of Sao Paulo, Sao Paulo, Brazil.
  • Nicacio SP; Department of Clinical Surgery, State University of Londrina, Londrina, Brazil.
  • Doty RL; Department of Clinical Surgery, State University of Londrina, Londrina, Brazil.
  • Pinna FR; Department of Otorhinolaryngology-Head and Neck Surgery, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, USA.
  • Voegels RL; Department of Otorhinolaryngology, University of Sao Paulo, Sao Paulo, Brazil.
  • Fornazieri MA; Department of Otorhinolaryngology, University of Sao Paulo, Sao Paulo, Brazil.
Acta Otolaryngol ; 143(2): 201-204, 2023 Feb.
Article em En | MEDLINE | ID: mdl-36861186
BACKGROUND: Previous studies demonstrated the difficulty of patients with Head and Neck Cancer (HNC) in sensing food taste, a function in which olfaction has a significant role. However, neither study employed psychophysical tests or control groups to establish the veracity of such complaints. AIMS/OBJECTIVES: In this study, we quantitatively tested the olfactory function of HNC individuals and compared their function to that of healthy controls. METHODS: Thirty-one HNC naïve treatment patients and thirty-one controls, matched for sex, age, schooling, and smoking, were tested with the University of Pennsylvania Smell Identification Test (UPSIT). RESULTS: The olfactory function was significantly worse among the patients diagnosed with head and neck cancer [UPSIT cancer = 22.9(CI 95%: 20.5-25.4) vs. UPSIT controls = 29.1(CI 95%: 26.9-31.3); p < .001]. Most patients with HNC had olfactory disorders (n = 29, 93.5%). The risk of olfactory loss was higher in the cancer group [OR: 10.5(CI 95%: 2.1-51.9; p = .001)]. CONCLUSION AND SIGNIFICANCE: Olfactory disorders can be detected in more than 90% of patients with head and neck cancer when evaluated using a well-validated olfactory test. Smell disorders may be a potential marker for early diagnosis of HNC.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias de Cabeça e Pescoço / Transtornos do Olfato Tipo de estudo: Diagnostic_studies / Etiology_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Limite: Humans Idioma: En Revista: Acta Otolaryngol Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Brasil País de publicação: Reino Unido

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias de Cabeça e Pescoço / Transtornos do Olfato Tipo de estudo: Diagnostic_studies / Etiology_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Limite: Humans Idioma: En Revista: Acta Otolaryngol Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Brasil País de publicação: Reino Unido